CONTEXT AND OBJECTIVE: Patients with advanced head and neck (H/N) and esophageal squamous cell carcinoma (SCC) often have a poor performance status and a dire prognosis. Our aim was to evaluate the feasibility, activity and quality of life (QOL) of an outpatient chemotherapy regimen consisting of cisplatin, 5-fluorouracil and leucovorin (CFL).
RESULTS:
The overall response rate was 36%, and the mean overall survival and progression-free survival were six and three months, respectively. We observed grade 3 or higher hematological toxicity in seven patients and one patient had grade 3 nausea and vomiting. One patient died because of neutropenic fever. Seven out of the 12 patients who could be evaluated regarding QOL presented an improvement in their overall health status and functional QOL scores over the course of the treatment.
INTRODUCTION
Squamous cell carcinoma (SCC) of the head and neck and esophagus is a common type of neoplasia in developing countries such as Brazil. Chemotherapy is an important part of the multidisciplinary treatment for SCC patients, and the overall and clinical complete response rates for combined chemotherapy schemes among previously treated SCC patients are 15% and 55%, respectively. 1 The most frequently used chemotherapy regimen includes four to five days continuous infusion of 5-fluorouracil and bolus cisplatin. [2] [3] [4] [5] In our country, the expense of pumps for continuous outpatient chemotherapy infusion, together with the scarcity of beds for elective admissions for palliative chemotherapy in an inpatient setting, prompted us to develop a protocol that could be administered without the need for hospital admission.
OBJECTIVE
The present study had the aim of evaluating the combination of bolus cisplatin, 5-fluorouracil and leucovorin (CFL) in patients with advanced (residual, metastatic or recurrent) SCC of the head and neck and esophagus, with a view to obtaining a feasible and low-cost chemotherapy regimen to circumvent the need for infusion pumps and/or hospital admission.
METHODS
Nonconsecutive patients with advanced or recurrent histologically confirmed head and neck and esophageal SCC were prospectively enrolled in this trial from January 2005 to June 2006, in Hospital Estadual Mário Covas, Santo André, São Paulo, Brazil. Since this was a pilot study, no sample size estimation was carried out before starting. All patients had to be 18 years of age or older, with normal renal function, measurable disease according to the response evaluation criteria in solid tumors (RECIST) 6 and Karnofsky 7 performance status (KPS) greater than or equal to 50%. This study had previously been approved by our institution's Research Ethics Committee.
After disease staging by means of computed tomography (CT) scans, the patients received leucovorin 20 mg/m 2 /day bolus infusions for four days (D1-D4), 5-fluorouracil 370 mg/m 2 /day bolus infusions for four days (D1-D4), and cisplatin 25 mg/m 2 /day in 90-minute infusions for three days (D1-D3), every 21 to 28 days, depending upon hematological recovery. This regimen was administered until hematological recovery or a state of intolerable toxicity was reached, or consent was withdrawn.
Quality of life (QOL) was evaluated using the European Organization for Research and Treatment of Cancer Quality of Life-C30 questionnaire (EORTC QLQ-C30) 8 at the beginning of the study and before each cycle. This questionnaire had previously been used in Portuguese. 9, 10 Toxicity was analyzed in accordance with the National Cancer Institute (NCI) criteria 11 before each cycle. KPS and clinical and laboratory parameters were also evaluated before each cycle. CT scans were repeated after third and sixth cycles of chemotherapy, in order to evaluate the responses.
RESULTS
Between January 2005 and June 2006, 15 patients were enrolled and received a total of 45 cycles. The median was three cycles per patient (ranging from one to six). The patients' characteristics are listed in Tables 1 and 2 . It is important to note that 80% of the enrolled patients' previous treatments had failed and their median KPS was 60%.
Eleven patients could be evaluated with regard to response to treatment. Four patients were excluded from this analysis because they received fewer than three cycles of CFL (exclusion reasons: one with poor KPS, one death due to neutropenic fever and two lost from follow-up). The overall response rate was 36% (four partial responses) (95% CI: 7 to 65%). Four patients had stable disease, yielding a clinical benefit rate of 72% (95% CI: 45 to 99%). The mean progression-free survival was three months, and the overall survival for all 15 participants was six months (Figure 1) .
The main observed toxicity was hematological: seven patients (53.9%) presented neutropenia of grade 3 or higher, two had neutropenic fever and one died as a consequence of it. Regarding nonhematological toxic effects, one patient had grade 3 nausea and vomiting.
Analysis of QOL using EORTC QLQ-C30 was only possible for 12 patients. Three patients received only one cycle and did not return afterwards. Seven patients (58%) presented an improvement in their overall health status and functional QOL scores over the course of the treatment (Figure 2) . We found no correlations between response to chemotherapy and improvement in QOL.
DISCUSSION
Treatments for head and neck and esophageal SCC have evolved over recent years through the introduction of modern irradiation techniques integrated with chemotherapy. Notwithstanding these advances, most patients still present with advanced disease and many of them end up progressing and eventually dying because of their disease. [12] [13] [14] [15] Therefore, it has become important to develop feasible, cheap and effective chemotherapy protocols to palliate symptoms and improve QOL.
The overall response rate with singleagent chemotherapy for patients with 
